589 related articles for article (PubMed ID: 20506527)
1. Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry.
Terrier B; Amoura Z; Ravaud P; Hachulla E; Jouenne R; Combe B; Bonnet C; Cacoub P; Cantagrel A; de Bandt M; Fain O; Fautrel B; Gaudin P; Godeau B; Harlé JR; Hot A; Kahn JE; Lambotte O; Larroche C; Léone J; Meyer O; Pallot-Prades B; Pertuiset E; Quartier P; Schaerverbeke T; Sibilia J; Somogyi A; Soubrier M; Vignon E; Bader-Meunier B; Mariette X; Gottenberg JE;
Arthritis Rheum; 2010 Aug; 62(8):2458-66. PubMed ID: 20506527
[TBL] [Abstract][Full Text] [Related]
2. Anti-CD20 therapy in patients with refractory systemic lupus erythematosus: a longitudinal analysis of 52 Hispanic patients.
Garcia-Carrasco M; Mendoza-Pinto C; Sandoval-Cruz M; Soto-Vega E; Beltran-Castillo A; Jimenez-Hernandez M; Graillet D; Gonzalez L; Rojas-Rodriguez J; Pineda-Almazana A; Zamudio-Huerta L; Lopez-Colombo A
Lupus; 2010 Feb; 19(2):213-9. PubMed ID: 19965944
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of rituximab in severe juvenile dermatomyositis: results from 9 patients from the French Autoimmunity and Rituximab registry.
Bader-Meunier B; Decaluwe H; Barnerias C; Gherardi R; Quartier P; Faye A; Guigonis V; Pagnier A; Brochard K; Sibilia J; Gottenberg JE; Bodemer C;
J Rheumatol; 2011 Jul; 38(7):1436-40. PubMed ID: 21677003
[TBL] [Abstract][Full Text] [Related]
4. Adverse events and efficacy of TNF-alpha blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients.
Aringer M; Houssiau F; Gordon C; Graninger WB; Voll RE; Rath E; Steiner G; Smolen JS
Rheumatology (Oxford); 2009 Nov; 48(11):1451-4. PubMed ID: 19748965
[TBL] [Abstract][Full Text] [Related]
5. Rituximab therapy for childhood-onset systemic lupus erythematosus.
Willems M; Haddad E; Niaudet P; Koné-Paut I; Bensman A; Cochat P; Deschênes G; Fakhouri F; Leblanc T; Llanas B; Loirat C; Pillet P; Ranchin B; Salomon R; Ulinski T; Bader-Meunier B;
J Pediatr; 2006 May; 148(5):623-627. PubMed ID: 16737873
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of rituximab in nonviral cryoglobulinemia vasculitis: data from the French Autoimmunity and Rituximab registry.
Terrier B; Launay D; Kaplanski G; Hot A; Larroche C; Cathébras P; Combe B; de Jaureguiberry JP; Meyer O; Schaeverbeke T; Somogyi A; Tricot L; Zénone T; Ravaud P; Gottenberg JE; Mariette X; Cacoub P
Arthritis Care Res (Hoboken); 2010 Dec; 62(12):1787-95. PubMed ID: 20740617
[TBL] [Abstract][Full Text] [Related]
7. Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry.
Gottenberg JE; Ravaud P; Bardin T; Cacoub P; Cantagrel A; Combe B; Dougados M; Flipo RM; Godeau B; Guillevin L; Le Loët X; Hachulla E; Schaeverbeke T; Sibilia J; Baron G; Mariette X;
Arthritis Rheum; 2010 Sep; 62(9):2625-32. PubMed ID: 20506353
[TBL] [Abstract][Full Text] [Related]
8. High-dose cyclophosphamide without stem cell transplantation in systemic lupus erythematosus.
Petri M; Jones RJ; Brodsky RA
Arthritis Rheum; 2003 Jan; 48(1):166-73. PubMed ID: 12528116
[TBL] [Abstract][Full Text] [Related]
9. Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases.
Gottenberg JE; Guillevin L; Lambotte O; Combe B; Allanore Y; Cantagrel A; Larroche C; Soubrier M; Bouillet L; Dougados M; Fain O; Farge D; Kyndt X; Lortholary O; Masson C; Moura B; Remy P; Thomas T; Wendling D; Anaya JM; Sibilia J; Mariette X;
Ann Rheum Dis; 2005 Jun; 64(6):913-20. PubMed ID: 15550531
[TBL] [Abstract][Full Text] [Related]
10. Longterm clinical and immunological effects of anti-CD20 treatment in patients with refractory systemic lupus erythematosus.
Lindholm C; Börjesson-Asp K; Zendjanchi K; Sundqvist AC; Tarkowski A; Bokarewa M
J Rheumatol; 2008 May; 35(5):826-33. PubMed ID: 18398943
[TBL] [Abstract][Full Text] [Related]
11. Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis.
Gunnarsson I; Sundelin B; Jónsdóttir T; Jacobson SH; Henriksson EW; van Vollenhoven RF
Arthritis Rheum; 2007 Apr; 56(4):1263-72. PubMed ID: 17393458
[TBL] [Abstract][Full Text] [Related]
12. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab.
Looney RJ; Anolik JH; Campbell D; Felgar RE; Young F; Arend LJ; Sloand JA; Rosenblatt J; Sanz I
Arthritis Rheum; 2004 Aug; 50(8):2580-9. PubMed ID: 15334472
[TBL] [Abstract][Full Text] [Related]
13. Rituximab infusion-related adverse event rates are lower in patients with systemic lupus erythematosus than in those with rheumatoid arthritis.
Conti F; Ceccarelli F; Perricone C; Alessandri C; Conti V; Massaro L; Truglia S; Spinelli FR; Spadaro A; Valesini G
Rheumatology (Oxford); 2011 Jun; 50(6):1148-52. PubMed ID: 21278072
[TBL] [Abstract][Full Text] [Related]
14. Umbilical cord mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus.
Sun L; Wang D; Liang J; Zhang H; Feng X; Wang H; Hua B; Liu B; Ye S; Hu X; Xu W; Zeng X; Hou Y; Gilkeson GS; Silver RM; Lu L; Shi S
Arthritis Rheum; 2010 Aug; 62(8):2467-75. PubMed ID: 20506343
[TBL] [Abstract][Full Text] [Related]
15. Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and re-treatment.
Smith KG; Jones RB; Burns SM; Jayne DR
Arthritis Rheum; 2006 Sep; 54(9):2970-82. PubMed ID: 16947528
[TBL] [Abstract][Full Text] [Related]
16. Rituximab induces a rapid and sustained remission in Colombian patients with severe and refractory systemic lupus erythematosus.
Pinto LF; Velásquez CJ; Prieto C; Mestra L; Forero E; Márquez JD
Lupus; 2011 Oct; 20(11):1219-26. PubMed ID: 21784778
[TBL] [Abstract][Full Text] [Related]
17. Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus.
Petri M; Stohl W; Chatham W; McCune WJ; Chevrier M; Ryel J; Recta V; Zhong J; Freimuth W
Arthritis Rheum; 2008 Aug; 58(8):2453-9. PubMed ID: 18668552
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study.
Aringer M; Graninger WB; Steiner G; Smolen JS
Arthritis Rheum; 2004 Oct; 50(10):3161-9. PubMed ID: 15476222
[TBL] [Abstract][Full Text] [Related]
19. Treatment of refractory SLE with rituximab plus cyclophosphamide: clinical effects, serological changes, and predictors of response.
Jónsdóttir T; Gunnarsson I; Risselada A; Henriksson EW; Klareskog L; van Vollenhoven RF
Ann Rheum Dis; 2008 Mar; 67(3):330-4. PubMed ID: 17827182
[TBL] [Abstract][Full Text] [Related]
20. B cell depletion therapy for 19 patients with refractory systemic lupus erythematosus.
Podolskaya A; Stadermann M; Pilkington C; Marks SD; Tullus K
Arch Dis Child; 2008 May; 93(5):401-6. PubMed ID: 18039744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
